Core Viewpoint - Goldman Sachs initiates coverage on Connora-B (02162) with a "Buy" rating and a target price of HKD 92.67 [1] Group 1: Product Approval and Market Potential - The company's first commercial product, Stapokibart, has been approved in mainland China for atopic dermatitis, chronic sinusitis, and seasonal allergic rhinitis [1] - With Stapokibart's first-mover advantage in these areas, it is expected to establish a valuation foundation for the company, with peak sales projected to exceed RMB 5 billion by 2035 [1] Group 2: Future Growth Drivers - Greater growth momentum is anticipated from CM512, which is believed to be a superior option for asthma and chronic obstructive pulmonary disease [1] - Global sales for CM512 are expected to reach USD 3.3 billion before the point of sale (PoS) stage and USD 694 million after by 2035 [1]
高盛：首予康诺亚-B(02162)买入评级 目标价92.67港元